Clarivate Epidemiology’s coverage of mesothelioma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
Clarivate Epidemiology’s coverage of postherpetic neuralgia (PHN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
MARKET OUTLOOKPolycythemia vera (PV) is a rare hematological malignancy estimated to affect 50,000 people in the United States. Patients can be classified as having low- or high-risk PV, each of…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Pulmonary hypertension disease patient populations, covering 171…
Clarivate Epidemiology’s coverage of acute prophylaxis for venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets…
Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of PH…
Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed prevalence of…
Clarivate Epidemiology’s coverage of soft tissue sarcoma (STS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of soft tissue sarcoma (STS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate’s Epidemiology’s coverage of Soft tissue sarcoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Soft tissue…